AstraZeneca, Daiichi Sankyo seek US FDA's accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC

Source :: PharmaBiz. November 13, 2024
Publication Year :: 2024
Abstract: AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally [...]

Subjects :: AstraZeneca PLC
Metastasis -- Drug therapy
Lung cancer, Non-small cell -- Drug therapy
Drug approval
Clinical trials
Epidermal growth factor
Pharmaceutical industry
Pharmaceuticals and cosmetics industries

Tools